The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Etherna Immunotherapies competitive analysis

Loading summary...

Latest oppositions filed by Etherna Immunotherapies

Explore patent oppositions filed by Etherna Immunotherapies against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3853305
High-Purity Peg Lipids And Uses ThereofMODERNAJun 27, 2025
EP3283059
Method For Producing Rna CompositionsCUREVACOct 3, 2024
EP3590949
Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses ThereofMODERNAFeb 20, 2023
EP2791160
Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNADec 2, 2022
EP3682905
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMODERNAAug 31, 2022
EP3173092
Rna Containing Composition For Treatment Of Tumor DiseasesCUREVACMar 26, 2020
EP3153179
Optimised Injection Formulation For MrnaCUREVACMar 18, 2020
EP3292873
Combination Of Vaccination And Inhibition Of The Pd-1 PathwayCUREVACFeb 3, 2020
EP2216028
Immunostimulation By Chemically Modified RnaCUREVACSep 6, 2018
EP2958588
Combination Of Vaccination And Inhibition Of The Pd-1 PathwayCUREVACMay 23, 2018

Latest PTAB cases involving Etherna Immunotherapies

Discover the latest PTAB cases involving Etherna Immunotherapies, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Etherna Immunotherapies with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ETHERNA IMMUNOTHERAPIES10 - - -
CUREVAC - 62 - 1
CUREVAC MANUFACTURING - 24 - -
MODERNA57542